Dermatomyositis-like Eruptions, Hydroxyurea-Associated Squamous Dysplasia, and Nonmelanoma Skin Cancer: A Case Report and Systematic Review

Dermatomyositis-like Eruptions, Hydroxyurea-Associated Squamous Dysplasia, and Nonmelanoma Skin Cancer: A Case Report and Systematic Review

Hydroxyurea (HU), a cornerstone treatment for myeloproliferative disorders, is associated with a wide range of cutaneous side effects, from xerosis and hyperpigmentation to more severe conditions like dermatomyositis-like eruptions (DM-LE) and nonmelanoma skin cancers (NMSC), particularly squamous c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Giorgia Di Marco, Gianmarco Diego Bigotto, Eleonora Cossar, Nathalie Rizzo, Stefania Guida, Franco Rongioletti
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Series:	Dermatopathology
Subjects:	hydroxyurea-induced dermatitis dermatomyositis-like eruption hydroxyurea-associated squamous dysplasia hydroxyurea-associated squamous cell carcinoma p53 overexpression
Online Access:	https://www.mdpi.com/2296-3529/12/2/11
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hydroxyurea and nonmelanoma skin cancers: Report of three cases and review of the literature
by: Roš Tatjana, et al.
Published: (2017-01-01)

Multiple Skin Cancers Associated With Hydroxyurea: Case Report and Review of Literature
by: Safoura Shakoei, et al.
Published: (2025-08-01)

Human immunodeficiency virus Infection in a patient of chronic myelogenous leukemia
by: Vijay B Tuljapurkar, et al.
Published: (2013-01-01)

Influence of hydroxyurea on tubular phosphate handling in sickle cell nephropathy
by: Gabriela Araujo de Abreu, et al.
Published: (2024-11-01)

Optimization of hydroxyurea in sickle cell disease in Brazil
by: Clarisse Lobo, et al.
Published: (2025-04-01)

Incidence of avascular necrosis in patients with sickle cell anemia received hydroxyurea and blood transfusion: a comparative study
by: Asmaa Hassan Khudhair, et al.
Published: (2024-12-01)

Hydroxyurea mitigates diabetic kidney disease through mTOR-S6K signaling pathway in STZ-induced diabetic mice
by: Wanying Cheng, et al.
Published: (2025-01-01)

An unexpected cause of severe metabolic acidosis
by: Suzanne K. Veneman, et al.
Published: (2025-05-01)

Sickle Cell Anemia Treatment With Hydroxyurea in Low-Resource Settings: Challenges and Opportunities for Global North-South Collaboration
by: Teresa S. Latham
Published: (2025-01-01)

A simplified hydroxyurea dosing approach for paediatric sickle cell anaemia in nigeria: addressing emergency care burden and adherence barriers in low-resource settings
by: Chisom Nri-Ezedi, et al.
Published: (2025-07-01)

Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial
by: Vincent Mboizi, et al.
Published: (2024-12-01)

In vitro study of anti-sickling effects of aqueous extracts of Garcinia kola (seeds), Zingiber officinale (rhizomes) and Allium sativum(bulbs) on sodium metabisulphite-treated HBSS erythrocytes
by: M. O. Salawu, et al.
Published: (2025-07-01)

Pseudotumor Cerebri and Sickle Cell Disease
by: J Gordon Millichap
Published: (2004-03-01)

Primary Stroke Screening and Hydroxyurea Treatment for Sickle Cell Anemia in Pediatric Healthcare Settings in East and Central Africa: A Narrative Review of Capacity Gaps and Opportunities
by: Teresa Smith Latham, et al.
Published: (2025-05-01)

Association of Fetal Hemoglobin and Auto-splenectomy in Saudi Adults with Sickle Cell Disease: A Retrospective Study
by: Ibtihal S Alsaad, et al.
Published: (2025-04-01)

The induction effect of hydroxyurea and metformin on fetal globin in the K562 cell line
by: Mohammad Eini, et al.
Published: (2025-04-01)

Impact of Xmn1 polymorphism on hydroxyurea therapy in children with HbE-β non-transfusion dependent thalassemia: a cohort study
by: Saheli Roy, et al.
Published: (2025-06-01)

Identifying and addressing underuse in hematologic care through systems-based hematology
by: Jacob C. Cogan, et al.
Published: (2025-05-01)

Observational Study on Hematological Adverse Drug Reactions (HADRs) from Hydroxyurea in Pediatric Patients with Sickle Cell Disease (SCD): Assessing Prevalence, Causality, Severity, Preventability, and Predictability, along with Clinical Management by a Clinical Pharmacist at a Tertiary Care Teaching Hospital
by: Rajesh Hadia, et al.
Published: (2025-01-01)

Multiple cardiac surgical procedures in a case of an octogenarian with essential thrombocythemia
by: Motohiro Maeda, et al.
Published: (2023-06-01)

An Analysis of the Body Mass Index and Lipid Profiles in Saudi Patients with Sickle Cell Disease: A Case Control Study
by: Rehab Y. Al-Ansari, et al.
Published: (2025-04-01)

HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE
by: Giovanna Cannas, et al.
Published: (2017-02-01)

Cerebrovascular Accident in a Patient with Polycythemia: a Case Report
by: O. M. Drapkina, et al.
Published: (2022-03-01)

Is Hydroxyurea Treatment Changing the Life of Children with Sickle Cell Disease?
by: Mohammed Ali Al Sabbah, et al.
Published: (2023-07-01)

THE DEPOSIT OF ANTIBODY’S PROLIFERATIVE ACTIVITY IN THE IMMUNE RESPONSE AND ITS RESISTANCE TO INHIBITORS OF PROLIFERATION
by: E. D. Gavrilova, et al.
Published: (2012-05-01)

The Veiled Enigma: Uncovering Subcutaneous Panniculitis-like Cutaneous T-cell Lymphoma
by: Bangaru Hanumaiah, et al.
Published: (2025-04-01)

An In vitro investigation of Lactobacillus plantarum F4 Strain’s Anti-sickling and Fetal Hemoglobin Inducing Effects on Sickled Erythrocytes
by: Firdosh Shah, et al.
Published: (2025-03-01)

Hydrophylic interaction chromatography used for separation of hydroxycarbamide and urea
by: A. S. Osipov, et al.
Published: (2018-02-01)

Development of eruptive keratoacanthoma-like squamous atypia after biologic therapy
by: Stephen Li, MD, PhD, et al.
Published: (2025-08-01)

Chromatographic column with nitrile sorbent USED in the analysis of hydroxycarbamide by hydrophilic interaction liquid chromatography
by: A. S. Osipov, et al.
Published: (2018-02-01)

Mycophenolate mofetil after tacrolimus for refractory clinically amyopathic dermatomyositis: a case report
by: Gui-Chen Ling, et al.
Published: (2024-10-01)

Spontaneous pneumomediastinum in dermatomyositis
by: Ankit Jain, et al.
Published: (2017-01-01)

Psoriasis in a patient with dermatomyositis
by: Pavlović Miloš D., et al.
Published: (2004-01-01)

Diagnosis and Clinical Management of Esophageal Squamous Dysplasia
by: Gwang Ha Kim
Published: (2021-03-01)

PANNICULITIS IN DERMATOMYOSITIS
by: O. A. Antelava, et al.
Published: (2016-07-01)

Dermatomyositis: difficuities of diagnostic search
by: M. M. Tlish, et al.
Published: (2023-07-01)

Multisystemic Complications and Rapid Decline in Anti‐MDA‐5 Positive Amyopathic Dermatomyositis: A Case Study
by: Hem Prajapati, et al.
Published: (2025-03-01)

Dermatomyositis-Related Encephalopathy: Clinical, Neuroimaging and Immunological Characterization
by: Daniel Alberto Carrillo-Vázquez, et al.
Published: (2025-03-01)

Clinical characteristics and prognosis of anti-MDA5 antibody positive dermatomyositis patients with secondary interstitial lung disease
by: MA Zongbo, et al.
Published: (2024-12-01)

Role of stromal myofibroblasts in the progression of oral lesions from dysplasia to invasive carcinoma
by: Aeman Khalid, et al.
Published: (2019-01-01)